FY2027 Earnings Forecast for Denali Therapeutics Inc. (NASDAQ:DNLI) Issued By HC Wainwright

Denali Therapeutics Inc. (NASDAQ:DNLI) – Stock analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued on Wednesday, May 8th. HC Wainwright analyst A. Fein now expects that the company will earn $1.99 per share for the year, up from their prior forecast of $1.94. HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2028 earnings at $4.48 EPS.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter in the previous year, the company posted ($0.80) earnings per share.

Other equities research analysts have also recently issued reports about the company. UBS Group dropped their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. Wedbush cut their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday. Stifel Nicolaus lowered their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, The Goldman Sachs Group reduced their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, February 29th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $40.22.

Denali Therapeutics Trading Down 1.2 %

NASDAQ DNLI opened at $18.67 on Thursday. The firm has a market cap of $2.66 billion, a price-to-earnings ratio of -17.29 and a beta of 1.39. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.31. The company has a 50 day moving average of $18.77 and a 200-day moving average of $18.84.

Institutional Trading of Denali Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DNLI. CWM LLC raised its position in Denali Therapeutics by 216.7% in the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock valued at $43,000 after buying an additional 1,376 shares during the last quarter. Assetmark Inc. increased its stake in Denali Therapeutics by 49.1% in the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock valued at $44,000 after buying an additional 707 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after buying an additional 807 shares in the last quarter. Fisher Asset Management LLC bought a new position in shares of Denali Therapeutics in the 4th quarter valued at about $59,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Denali Therapeutics by 96.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,526 shares of the company’s stock valued at $73,000 after acquiring an additional 1,732 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Activity

In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total transaction of $30,471.14. Following the transaction, the director now owns 118,043 shares in the company, valued at $2,159,006.47. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, Director Steve E. Krognes sold 92,500 shares of the firm’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the sale, the director now owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the sale, the director now directly owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The disclosure for this sale can be found here. Insiders have sold a total of 110,955 shares of company stock valued at $2,218,802 in the last 90 days. 7.90% of the stock is owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.